TRAIL-induced apoptosis and proteasomal activity - Mechanisms, signalling and interplay

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Programmed cell death, including apoptosis, is crucial for development, tissue homeostasis, and cancer therapy.
• Targeting TRAIL (TNF-related apoptosis-inducing ligand) death receptors and proteasome inhibitors are established anti-cancer strategies.
• The interaction between TRAIL signaling and proteasomal regulation of cellular proteostasis is complex but therapeutically exploitable.

Purpose of the Study:

• To provide detailed insights into TRAIL-induced pathways and proteasome activity.
• To explore the mechanisms of action and pharmaceutical druggability of TRAIL and proteasome inhibitors.
• To elucidate how the interplay between these pathways can be leveraged for enhanced cancer cell killing.

Main Methods:

• Review of existing literature on TRAIL signaling pathways.
• Analysis of proteasome function and its role in cellular proteostasis.
• Examination of preclinical and clinical data on combination therapies involving TRAIL agonists and proteasome inhibitors.

Main Results:

• TRAIL-mediated apoptosis and proteasome inhibition represent distinct yet interconnected cellular processes.
• Synergistic effects are observed when TRAIL pathways are combined with proteasome inhibitors, leading to enhanced cancer cell death.
• Understanding the molecular crosstalk is essential for optimizing combination treatment strategies.

Conclusions:

• Combination therapy targeting TRAIL death receptors and proteasome activity offers a promising strategy for cancer treatment.
• Further research into the intricate signaling networks can refine therapeutic approaches.
• This review provides a comprehensive overview to guide the development of novel anti-cancer treatments.